344 related articles for article (PubMed ID: 28370444)
1. The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries.
Caballero T; Aberer W; Longhurst HJ; Maurer M; Zanichelli A; Perrin A; Bouillet L; Andresen I;
J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1214-1222. PubMed ID: 28370444
[TBL] [Abstract][Full Text] [Related]
2. Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey.
Maurer M; Bork K; Martinez-Saguer I; Aygören-Pürsün E; Botha J; Andresen I; Magerl M
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):163-169. PubMed ID: 30176179
[TBL] [Abstract][Full Text] [Related]
3. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant.
Bouillet L; Boccon-Gibod I; Launay D; Gompel A; Kanny G; Fabien V; Fain O;
Immun Inflamm Dis; 2017 Mar; 5(1):29-36. PubMed ID: 28250922
[TBL] [Abstract][Full Text] [Related]
4. Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals.
Hernández Fernandez de Rojas D; Ibañez E; Longhurst H; Maurer M; Fabien V; Aberer W; Bouillet L; Zanichelli A; Caballero T;
Int Arch Allergy Immunol; 2015; 167(1):21-8. PubMed ID: 26112099
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting.
Maurer M; Longhurst HJ; Fabien V; Li HH; Lumry WR
Allergy Asthma Proc; 2014; 35(5):377-81. PubMed ID: 25198193
[TBL] [Abstract][Full Text] [Related]
6. Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
Longhurst HJ; Zanichelli A; Caballero T; Bouillet L; Aberer W; Maurer M; Fain O; Fabien V; Andresen I;
Clin Exp Immunol; 2017 Apr; 188(1):148-153. PubMed ID: 27936514
[TBL] [Abstract][Full Text] [Related]
7. Icatibant use in Brazilian patients with hereditary angioedema (HAE) type 1 or 2 and HAE with normal C1-INH levels: findings from the Icatibant Outcome Survey Registry Study.
Grumach AS; Henriques MT; Bardou MLD; Pontarolli DA; Botha J; Correa M;
An Bras Dermatol; 2022; 97(4):448-457. PubMed ID: 35654647
[TBL] [Abstract][Full Text] [Related]
8. Icatibant Outcome Survey in Patients with Hereditary Angioedema: Experience in Israel Compared with Other Countries.
Toubi E; Kivity S; Graif Y; Reshef A; Botha J; Andresen I
Isr Med Assoc J; 2018 Apr; 20(4):227-232. PubMed ID: 29629730
[TBL] [Abstract][Full Text] [Related]
9. Icatibant as acute treatment for hereditary angioedema in adults.
Farkas H
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):779-88. PubMed ID: 27123689
[TBL] [Abstract][Full Text] [Related]
10. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
Farkas H; Reshef A; Aberer W; Caballero T; McCarthy L; Hao J; Nothaft W; Schranz J; Bernstein JA; Li HH
J Allergy Clin Immunol Pract; 2017; 5(6):1671-1678.e2. PubMed ID: 28601641
[TBL] [Abstract][Full Text] [Related]
11. First report of icatibant treatment in a pregnant patient with hereditary angioedema.
Farkas H; Kőhalmi KV; Veszeli N; Tóth F; Varga L
J Obstet Gynaecol Res; 2016 Aug; 42(8):1026-8. PubMed ID: 27093898
[TBL] [Abstract][Full Text] [Related]
12. The Icatibant Outcome Survey: 10 years of experience with icatibant for patients with hereditary angioedema.
Maurer M; Aberer W; Caballero T; Bouillet L; Grumach AS; Botha J; Andresen I; Longhurst HJ;
Clin Exp Allergy; 2022 Sep; 52(9):1048-1058. PubMed ID: 35861129
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility.
Otani IM; Lumry WR; Hurwitz S; Li HH; Craig TJ; Holtzman NS; Iandoli MI; Tucker J; Riedl MA; Zuraw BL; Banerji A
J Allergy Clin Immunol Pract; 2017; 5(2):442-447.e1. PubMed ID: 27818136
[TBL] [Abstract][Full Text] [Related]
14. Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain.
Guilarte M; Sala-Cunill A; Baeza ML; Cabañas R; Hernández MD; Ibañez E; de Larramendi CH; Lleonart R; Lobera T; Marqués L; de San Pedro BS; Botha J; Andresen I; Caballero T;
Allergy Asthma Clin Immunol; 2021 Dec; 17(1):137. PubMed ID: 34965883
[TBL] [Abstract][Full Text] [Related]
15. Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks.
Hide M; Horiuchi T; Ohsawa I; Andresen I; Fukunaga A
Allergol Int; 2021 Jan; 70(1):45-54. PubMed ID: 32919903
[TBL] [Abstract][Full Text] [Related]
16. Costs and effects of on-demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients.
Federici C; Perego F; Borsoi L; Crosta V; Zanichelli A; Gidaro A; Tarricone R; Cicardi M
BMJ Open; 2018 Jul; 8(7):e022291. PubMed ID: 30061443
[TBL] [Abstract][Full Text] [Related]
17. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.
Lumry WR; Farkas H; Moldovan D; Toubi E; Baptista J; Craig T; Riedl M
Int Arch Allergy Immunol; 2015; 168(1):44-55. PubMed ID: 26556097
[TBL] [Abstract][Full Text] [Related]
18. Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom.
Longhurst HJ; Dempster J; Lorenzo L; Buckland M; Grigoriadou S; Symons C; Bethune C; Fabien V; Bangs C; Garcez T
Allergy Asthma Clin Immunol; 2018; 14():28. PubMed ID: 30127805
[TBL] [Abstract][Full Text] [Related]
19. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.
Baş M; Greve J; Hoffmann TK; Reshef A; Aberer W; Maurer M; Kivity S; Farkas H; Floccard B; Arcoleo F; Martin L; Sitkauskiene B; Bouillet L; Schmid-Grendelmeier P; Li H; Zanichelli A
Allergy; 2013 Nov; 68(11):1452-9. PubMed ID: 24111645
[TBL] [Abstract][Full Text] [Related]
20. Modeling Cost-Effectiveness of On-Demand Treatment for Hereditary Angioedema Attacks.
Bernstein JA; Tyson C; Relan A; Adams P; Magar R
J Manag Care Spec Pharm; 2020 Feb; 26(2):203-210. PubMed ID: 31841366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
